OTLK logo

Outlook Therapeutics (OTLK)

Profile

Full Name

Outlook Therapeutics, Inc.

Ticker Symbol

OTLK

Exchange

NASDAQ

Country

United States

IPO

June 14, 2016

Indexes

Not included

Employees

23

Key Details

Price

$1.36(-2.16%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$4.06(+13.98% YoY)

PE ratio

-

Next earnings date

May 16, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 24, 25 Ascendiant Capital
Buy
Feb 18, 25 HC Wainwright & Co.
Buy
Feb 18, 25 Chardan Capital
Neutral
Jan 17, 25 HC Wainwright & Co.
Buy
Jan 17, 25 Guggenheim
Buy
Dec 2, 24 Chardan Capital
Neutral
Nov 29, 24 HC Wainwright & Co.
Buy
Nov 29, 24 BTIG
Buy
Aug 16, 24 Chardan Capital
Buy
Aug 15, 24 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for Outlook Therapeutics?
  • Does Outlook Therapeutics pay dividends?
  • What sector is Outlook Therapeutics in?
  • What industry is Outlook Therapeutics in?
  • What country is Outlook Therapeutics based in?
  • When did Outlook Therapeutics go public?
  • Is Outlook Therapeutics in the S&P 500?
  • Is Outlook Therapeutics in the NASDAQ 100?
  • Is Outlook Therapeutics in the Dow Jones?
  • When was Outlook Therapeutics's last earnings report?
  • When does Outlook Therapeutics report earnings?
  • Should I buy Outlook Therapeutics stock now?

What is the ticker symbol for Outlook Therapeutics?

The ticker symbol for Outlook Therapeutics is NASDAQ:OTLK

Does Outlook Therapeutics pay dividends?

No, Outlook Therapeutics does not pay dividends

What sector is Outlook Therapeutics in?

Outlook Therapeutics is in the Healthcare sector

What industry is Outlook Therapeutics in?

Outlook Therapeutics is in the Biotechnology industry

What country is Outlook Therapeutics based in?

Outlook Therapeutics is headquartered in United States

When did Outlook Therapeutics go public?

Outlook Therapeutics's initial public offering (IPO) was on June 14, 2016

Is Outlook Therapeutics in the S&P 500?

No, Outlook Therapeutics is not included in the S&P 500 index

Is Outlook Therapeutics in the NASDAQ 100?

No, Outlook Therapeutics is not included in the NASDAQ 100 index

Is Outlook Therapeutics in the Dow Jones?

No, Outlook Therapeutics is not included in the Dow Jones index

When was Outlook Therapeutics's last earnings report?

Outlook Therapeutics's most recent earnings report was on Feb 14, 2025

When does Outlook Therapeutics report earnings?

The next expected earnings date for Outlook Therapeutics is May 16, 2025

Should I buy Outlook Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page